Hansoh Pharmaceutical Group Company Limited
HNSPF
$5.20
$0.4910.40%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.70B | 1.69B | 1.68B | 1.55B | 1.42B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.70B | 1.69B | 1.68B | 1.55B | 1.42B |
| Cost of Revenue | 155.23M | 153.05M | 150.60M | 148.04M | 146.05M |
| Gross Profit | 1.55B | 1.54B | 1.53B | 1.40B | 1.28B |
| SG&A Expenses | 626.88M | 612.93M | 597.67M | 597.11M | 598.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.42M | 8.43M | 12.43M | 9.99M | 7.55M |
| Total Operating Expenses | 1.16B | 1.13B | 1.09B | 1.07B | 1.05B |
| Operating Income | 542.05M | 565.18M | 587.52M | 482.08M | 376.88M |
| Income Before Tax | 706.57M | 726.78M | 745.85M | 637.58M | 530.02M |
| Income Tax Expenses | 99.15M | 96.08M | 92.85M | 80.79M | 68.87M |
| Earnings from Continuing Operations | 607.42 | 630.70 | 653.00 | 556.78 | 461.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 607.42M | 630.70M | 653.00M | 556.78M | 461.15M |
| EBIT | 542.05M | 565.18M | 587.52M | 482.08M | 376.88M |
| EBITDA | 594.25M | 617.38M | 639.62M | 532.48M | 425.74M |
| EPS Basic | 0.10 | 0.11 | 0.11 | 0.09 | 0.08 |
| Normalized Basic EPS | 0.07 | 0.08 | 0.08 | 0.07 | 0.06 |
| EPS Diluted | 0.10 | 0.10 | 0.11 | 0.09 | 0.07 |
| Normalized Diluted EPS | 0.07 | 0.08 | 0.08 | 0.07 | 0.05 |
| Average Basic Shares Outstanding | 23.72B | 23.71B | 23.70B | 23.70B | 23.70B |
| Average Diluted Shares Outstanding | 23.80B | 23.94B | 24.08B | 24.08B | 24.08B |
| Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 |
| Payout Ratio | 42.63% | 27.74% | 13.81% | 16.20% | 19.55% |